## Contents

**List of contributors** ix  
**Preface** xiii  
**Acknowledgements** xv

---

### Section 1. The role of clinical trials in therapy development

1. **The impact of clinical trials in neurology** 1  
   E. Ray Dorsey and S. Claiborne Johnston

2. **The sequence of clinical development** 8  
   R. Michael Poole

3. **Unique challenges in the development of therapies for neurological disorders** 19  
   Gilmore N. O’Neill

---

### Section 2. Concepts in biostatistics and clinical measurement

4. **Fundamentals of biostatistics** 28  
   Judith Bebchuk and Janet Wittes

5. **Bias and random error** 42  
   Susan S. Ellenberg and Jacqueline A. French

6. **Approaches to data analysis** 52  
   William R. Clarke

7. **Selecting outcome measures** 69  
   Robert G. Holloway and Andrew D. Siderowf

---

### Section 3. Special study designs and methods for data monitoring

8. **Selection and futility designs** 78  
   Bruce Levin

9. **Adaptive design across stages of therapeutic development** 91  
   Christopher S. Coffey

10. **Crossover designs** 101  
    Mary E. Putt

11. **Two-period designs for evaluation of disease-modifying treatments** 113  
    Michael P. McDermott

---

### Section 4. Ethical issues

12. **Enrichment designs** 127  
    Kathryn M. Kellogg and John Markman

13. **Non-inferiority trials** 135  
    Rick Chappell

14. **Monitoring of clinical trials: Interim monitoring, data monitoring committees, and group sequential methods** 147  
    Rickey E. Carter and Robert F. Woolson

15. **Clinical approaches to post-marketing drug safety assessment** 160  
    Gerald J. Dal Pan

---

### Section 5. Regulatory perspectives

16. **Ethics in clinical trials involving the central nervous system: Risk, benefit, justice, and integrity** 173  
    Jonathan Kimmelman

17. **The informed consent process: Compliance and beyond** 187  
    Scott Y. H. Kim

---

### Section 6. Clinical trials in common neurological disorders

18. **Evidentiary standards for neurological drugs and biologics approval** 197  
    Russell Katz

19. **Premarket review of neurological devices** 206  
    Eric A. Mann and Peter G. Como

---

20. **Parkinson’s disease** 215  
    Karl Kieburtz and Jordan Elm

21. **Alzheimer’s disease** 227  
    Joshua D. Grill and Jeffrey Cummings
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>Acute ischemic stroke 242</td>
</tr>
<tr>
<td></td>
<td>Devin L. Brown, Karen C. Johnston, and Yuko Y. Palesch</td>
</tr>
<tr>
<td>23</td>
<td>Multiple sclerosis 257</td>
</tr>
<tr>
<td></td>
<td>Richard A. Rudick, Elizabeth Fisher, and Gary R. Cutter</td>
</tr>
<tr>
<td>24</td>
<td>Amyotrophic lateral sclerosis 273</td>
</tr>
<tr>
<td></td>
<td>Nazem Atassi, David Schoenfeld, and Merit Cudkowicz</td>
</tr>
<tr>
<td>25</td>
<td>Epilepsy 284</td>
</tr>
<tr>
<td></td>
<td>John R. Pollard, Susan S. Ellenberg, and Jacqueline A. French</td>
</tr>
<tr>
<td>26</td>
<td>Insomnia 295</td>
</tr>
<tr>
<td></td>
<td>Michael E. Yurcheshen, Changyong Feng, and J. Todd Arnedt</td>
</tr>
</tbody>
</table>

### Section 7. Clinical trial planning and implementation

| 27      | Clinical trial planning: An academic and industry perspective 309   |
|         | Cornelia L. Kamp and Jean-Michel Germain                            |
| 28      | Clinical trial implementation, analysis, and reporting: An academic and industry perspective 338 |
|         | Cornelia L. Kamp and Jean-Michel Germain                            |
| 29      | Academic-industry collaborations and compliance issues 352          |
|         | D. Troy Morgan                                                      |

Index 362